Cargando…

Soy isoflavones avert chronic inflammation-induced bone loss and vascular disease

BACKGROUND: Evidence from epidemiological, clinical and animal studies suggests a link may exist between low bone density and cardiovascular disease, with inflammatory mediators implicated in the pathophysiology of both conditions. This project examined whether supplementation with soy isoflavones (...

Descripción completa

Detalles Bibliográficos
Autores principales: Droke, Elizabeth A, Hager, Kelly A, Lerner, Megan R, Lightfoot, Stan A, Stoecker, Barbara J, Brackett, Daniel J, Smith, Brenda J
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2007
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2034375/
https://www.ncbi.nlm.nih.gov/pubmed/17825101
http://dx.doi.org/10.1186/1476-9255-4-17
_version_ 1782136999537278976
author Droke, Elizabeth A
Hager, Kelly A
Lerner, Megan R
Lightfoot, Stan A
Stoecker, Barbara J
Brackett, Daniel J
Smith, Brenda J
author_facet Droke, Elizabeth A
Hager, Kelly A
Lerner, Megan R
Lightfoot, Stan A
Stoecker, Barbara J
Brackett, Daniel J
Smith, Brenda J
author_sort Droke, Elizabeth A
collection PubMed
description BACKGROUND: Evidence from epidemiological, clinical and animal studies suggests a link may exist between low bone density and cardiovascular disease, with inflammatory mediators implicated in the pathophysiology of both conditions. This project examined whether supplementation with soy isoflavones (IF), shown to have anti-inflammatory properties, could prevent tissue expression of TNF-α and the development of skeletal pathology in an animal model of chronic inflammation. METHODS: Eight-week old, intact, female C57BL/6J mice were used. In Phase 1, a lipopolysaccharide (LPS)-dose response study (0, 0.133, 1.33 and 13.3 μg/d) was conducted to determine the LPS dose to use in Phase 2. The results indicated the 1.33 μg LPS/d dose produced the greatest decrease in lymphocytes and increase in neutrophils. Subsequently, in Phase 2, mice were randomly assigned to one of six groups (n = 12–13 per group): 0 or 1.33 μg LPS/d (placebo or LPS) in combination with 0, 126 or 504 mg aglycone equivalents of soy IF/kg diet (Control, Low or High dose IF). Mice were fed IF beginning 2 wks prior to the 30-d LPS study period. RESULTS: At the end of the study, no differences were detected in final body weights or uterine weights. In terms of trabecular bone microarchitecture, μCT analyses of the distal femur metaphysis indicated that LPS significantly decreased trabecular bone volume (BV/TV) and number (TbN), and increased separation (TbSp). Trabecular bone strength (i.e. total force) and stiffness were also compromised in response to LPS. The High IF dose provided protection against these detrimental effects on microarchitecture, but not biomechanical properties. No alterations in trabecular thickness (TbTh), or cortical bone parameters were observed in response to the LPS or IF. Immunohistomchemical staining showed that tumor necrosis factor (TNF)-α was up-regulated by LPS in the endothelium of small myocardial arteries and arterioles as well as the tibial metaphysis and down-regulated by IF. CONCLUSION: These results suggest IF may attenuate the negative effects of chronic inflammation on bone and cardiovascular health. Additional research is warranted to examine the anti-inflammatory properties of the soy isoflavones and the mechanisms underlying their prevention of chronic inflammation-induced bone loss.
format Text
id pubmed-2034375
institution National Center for Biotechnology Information
language English
publishDate 2007
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-20343752007-10-18 Soy isoflavones avert chronic inflammation-induced bone loss and vascular disease Droke, Elizabeth A Hager, Kelly A Lerner, Megan R Lightfoot, Stan A Stoecker, Barbara J Brackett, Daniel J Smith, Brenda J J Inflamm (Lond) Research BACKGROUND: Evidence from epidemiological, clinical and animal studies suggests a link may exist between low bone density and cardiovascular disease, with inflammatory mediators implicated in the pathophysiology of both conditions. This project examined whether supplementation with soy isoflavones (IF), shown to have anti-inflammatory properties, could prevent tissue expression of TNF-α and the development of skeletal pathology in an animal model of chronic inflammation. METHODS: Eight-week old, intact, female C57BL/6J mice were used. In Phase 1, a lipopolysaccharide (LPS)-dose response study (0, 0.133, 1.33 and 13.3 μg/d) was conducted to determine the LPS dose to use in Phase 2. The results indicated the 1.33 μg LPS/d dose produced the greatest decrease in lymphocytes and increase in neutrophils. Subsequently, in Phase 2, mice were randomly assigned to one of six groups (n = 12–13 per group): 0 or 1.33 μg LPS/d (placebo or LPS) in combination with 0, 126 or 504 mg aglycone equivalents of soy IF/kg diet (Control, Low or High dose IF). Mice were fed IF beginning 2 wks prior to the 30-d LPS study period. RESULTS: At the end of the study, no differences were detected in final body weights or uterine weights. In terms of trabecular bone microarchitecture, μCT analyses of the distal femur metaphysis indicated that LPS significantly decreased trabecular bone volume (BV/TV) and number (TbN), and increased separation (TbSp). Trabecular bone strength (i.e. total force) and stiffness were also compromised in response to LPS. The High IF dose provided protection against these detrimental effects on microarchitecture, but not biomechanical properties. No alterations in trabecular thickness (TbTh), or cortical bone parameters were observed in response to the LPS or IF. Immunohistomchemical staining showed that tumor necrosis factor (TNF)-α was up-regulated by LPS in the endothelium of small myocardial arteries and arterioles as well as the tibial metaphysis and down-regulated by IF. CONCLUSION: These results suggest IF may attenuate the negative effects of chronic inflammation on bone and cardiovascular health. Additional research is warranted to examine the anti-inflammatory properties of the soy isoflavones and the mechanisms underlying their prevention of chronic inflammation-induced bone loss. BioMed Central 2007-09-07 /pmc/articles/PMC2034375/ /pubmed/17825101 http://dx.doi.org/10.1186/1476-9255-4-17 Text en Copyright © 2007 Droke et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License ( (http://creativecommons.org/licenses/by/2.0) ), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research
Droke, Elizabeth A
Hager, Kelly A
Lerner, Megan R
Lightfoot, Stan A
Stoecker, Barbara J
Brackett, Daniel J
Smith, Brenda J
Soy isoflavones avert chronic inflammation-induced bone loss and vascular disease
title Soy isoflavones avert chronic inflammation-induced bone loss and vascular disease
title_full Soy isoflavones avert chronic inflammation-induced bone loss and vascular disease
title_fullStr Soy isoflavones avert chronic inflammation-induced bone loss and vascular disease
title_full_unstemmed Soy isoflavones avert chronic inflammation-induced bone loss and vascular disease
title_short Soy isoflavones avert chronic inflammation-induced bone loss and vascular disease
title_sort soy isoflavones avert chronic inflammation-induced bone loss and vascular disease
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2034375/
https://www.ncbi.nlm.nih.gov/pubmed/17825101
http://dx.doi.org/10.1186/1476-9255-4-17
work_keys_str_mv AT drokeelizabetha soyisoflavonesavertchronicinflammationinducedbonelossandvasculardisease
AT hagerkellya soyisoflavonesavertchronicinflammationinducedbonelossandvasculardisease
AT lernermeganr soyisoflavonesavertchronicinflammationinducedbonelossandvasculardisease
AT lightfootstana soyisoflavonesavertchronicinflammationinducedbonelossandvasculardisease
AT stoeckerbarbaraj soyisoflavonesavertchronicinflammationinducedbonelossandvasculardisease
AT brackettdanielj soyisoflavonesavertchronicinflammationinducedbonelossandvasculardisease
AT smithbrendaj soyisoflavonesavertchronicinflammationinducedbonelossandvasculardisease